Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas
Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas is a paper indexed in PICO Portal from OpenAlex.
How many citations does Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas have?
Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas has 52 citations in the OpenAlex counts PICO Portal stores.
When was Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas published?
Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas has 2011 year in the PICO Portal index.
What is the open-access status of Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas?
Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas has bronze oa status in the PICO Portal index.
What is the DOI of Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas?
The DOI for Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas is on the source record.
What is the PMID of Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas?
The PMID for Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas is on the source record.
What is the OpenAlex record for Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas?
The OpenAlex for Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas is on the source record.